ClinicalTrials.gg
CompletedNCT02293148Updated Jul 24, 2018

Single Dose, Pharmacokinetic, Safety, Tolerability and QTc Study of GSK1278863 in Healthy Volunteers

A Phase 1 interventional study of GSK1278863 75 mg and GSK1278863 500 mg in Anaemia, sponsored by GlaxoSmithKline. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-07-24.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
61
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies testing GSK1278863 in Anemia — 1 open to participants now, 1 under way, 1 of them phase 3. GSK1278863 · Anemia.

Enrollment
19th of 30
61 · median 76
Started
2014
with 2 others
Phase 1
10 of 30
none open now
Registered
11th of 30
by date
Lead sponsor
28 of 30
GlaxoSmithKline

Among the 30 studies testing GSK1278863 in Anemia, this one is the 19th largest by enrollment, is one of 3 that started in 2014, is one of 10 in phase 1, and was the 11th registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

1 of the 30 studies testing GSK1278863 in Anemia is open now. Recruiting first, the newest first:

About GSK1278863

GSK1278863: first FDA approval 2023 (JESDUVROQ). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing GSK1278863 in Anemia, or all of them as a file.
02

Study summary

This study is being performed to comply with regulatory requirements that all new non-antiarrhythmic drugs must be assessed for potential effects on cardiac repolarization through electrocardiographic evaluation in a 'Thorough QT/ Corrected QT interval (TQT)' study. This will be a two part study, Part A will be an open-label, single oral dose study design in order to evaluate the pharmacokinetics, safety and tolerability of a 500 milligram (mg) dose of GSK1278863 and Part B will be a single-blind, randomized, placebo-controlled, single, oral dose, four-way crossover study design. Parts A and B will be conducted in healthy adult subjects with 12-lead electrocardiograms (ECGs), clinical laboratory safety tests, vital sign measurements, physical examinations, adverse event reports, and pharmacokinetic samples collected throughout the study.

03

Conditions studied

  • Anaemia

Browse trials for

Keywords

  • Prolyl hydroxylase inhibitor
  • GSK1278863
  • Anemia
  • QTc
  • erythropoiesis stimulating agent
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who are between 18 and 45 years and of age, inclusive at the time of signing the form
  • Healthy as determined by the investigator or medically qualified designee based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring obtained at the Screening visit.

The determination of clinical significance will be made by the Investigator and the GlaxoSmithKline (GSK) Medical Monitor and will require that the finding is unlikely to introduce additional risk factors or interfere with the study procedures, or the integrity of the study

  • values at screening greater than the lower limit of the laboratory reference range and less than or equal to 16.0 gram (g)/decilitre (dL) for males and less than or equal to 14.0 g/dL for females
  • No significant abnormality on 12-lead at screening, including the following specific requirements:

Ventricular rate >= 40 beats per minute; PR interval \<= 210milliseconds (msec); Q waves \< 30msec (up to 50msec permitted in lead III only); QRS interval to be >= 60msec and \< 120msec; The waveforms must enable the to be clearly defined; QTcF interval must be \< 450msec.

  • Body weight >= 50 kilograms (kg) and (BMI) within the range 19-29.9 kg/meter square (m\^2) (inclusive).
  • Female and Male:

Female subject is eligible to participate if she is not pregnant (as confirmed by a negative serum human chorionic gonadotrophin [hCG] test), not lactating, and at least one of the following conditions applies:

  • Non- defined as:
  • Pre-menopausal females with one of the following:
  • Documented tubal ligation
  • Documented hysteroscopic tubal occlusion procedure with follow-up confirmation of bilateral tubal occlusion
  • Hysterectomy
  • Documented Bilateral Oophorectomy
  • defined as 12 months of spontaneous amenorrhea [in questionable cases, a blood sample with simultaneous follicle stimulating hormone (FSH) 23.0-116.3 International Units (IU)/Litre (L) and estradiol \<=10 picograms (pg)/millilitre (mL) (or\<=37 Picomoles (pmol)/L) is confirmatory]. Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the highly effective methods if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrolment
  • Reproductive potential and agrees to follow the contraception requirement for female subjects from 30 days prior to the first dose of study treatment and until at least five terminal half-lives OR until any continuing pharmacologic effect has ended, whichever is longer after the last dose of study treatment and completion of the follow-up visit
  • Capable of giving signed informed consent and includes compliance with the requirements and restrictions listed in the consent form and in this protocol

Exclusion criteria

Exclusion Criteria:

  • Hypertensive (diastolic BP >90 millimetres of mercury [mmHg] or systolic BP >140 mmHg) at screening
  • A supine mean heart rate outside the range 50-100 beats per minute (bpm) at screening
  • Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)
  • (ALT), alkaline phosphatase and >1.5x (ULN) (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%)
  • History or presence of any medically significant disease, or any disorder that would introduce additional risk or interfere with the study procedures or outcome. In particular, a family history of , of early or sudden cardiac death or of early cardiovascular disease

NOTES:

  • The QTc is the QTcF interval
  • The specific formula that will be used to determine eligibility and discontinuation for an individual subject should be determined prior to initiation of the study. In other words, several different formulae cannot be used to calculate the QTc for an individual subject and then the lowest QTc value used to include or discontinue the subject from the trial
  • Serum calcium, magnesium or potassium levels outside the normal reference range
  • History of deep vein thrombosis, stroke, , pulmonary embolism or other thrombosis related condition within the last five years
  • History of myocardial infarction or acute coronary syndrome
  • Subjects with a pre-existing condition interfering with normal gastrointestinal anatomy or motility, and/or hepatic function that could interfere with the absorption, metabolism, and/or excretion of GSK1278863. Examples of conditions that could interfere with normal gastrointestinal anatomy or motility include gastrointestinal bypass surgery, partial or total gastrectomy, small bowel resection, vagotomy, malabsorption, Crohn's disease, ulcerative colitis, or celiac sprue
  • Evidence of active peptic, duodenal or esophageal ulcer disease at Screening OR history of gastrointestinal bleeding
  • Subjects with chronic inflammatory joint disease (e.g., scleroderma, systemic lupus erythematosis, rheumatoid arthritis)
  • Subjects with a history of pulmonary artery hypertension
  • Subjects with heart failure, as defined by the (NYHA) functional classification system, including known right heart failure
  • Subjects with a history of within the prior five years, who are receiving treatment for cancer, or who have a strong family history of cancer (e.g., familial cancer disorders); with the exception of squamous cell or basal cell carcinoma of the skin that has been definitively treated prior to screening through Day -1 (Randomization)
  • History of proliferative vascular eye disease (e.g., choroidal or retinal disease, such as neovascular age-related macular degeneration, proliferative diabetic retinopathy or macular edema)
  • Subjects must abstain from taking prescription or non-prescription drugs (including vitamins and dietary or herbal supplements) except occasional usage of acetaminophen, within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study treatment until completion of the follow-up visit, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study medications)
  • History of regular alcohol consumption within 6 months of the study defined as:

An average weekly intake of >14 drinks for males or >7 drinks for females. One drink is equivalent to 12 g of alcohol: 12 ounces (360 mL) of beer, 5 ounces (150 mL) of wine or 1.5 ounces (45 mL) of 80 proof distilled spirits

  • Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products prior to screening
  • History of regular use within 6 months of the study of tobacco- or nicotine-containing products
  • History of drug abuse or dependence within 6 months of the study
  • History of sensitivity to GSK1278863, or its components thereof, a history of sensitivity to quinolone antibiotics or components thereof, or a history of drug or other allergy that, in the opinion of the Investigator or GSK Medical Monitor, contraindicates their participation
  • Consumption of red wine, grapefruit (juice), blood orange (juice), star fruit, onions, kale, broccoli, green beans, or apples from 7 days prior to the first dose of study treatment until the Follow-up visit, unless in the opinion of the Investigator and GSK Medical Monitor this will not interfere with the study procedures and compromise subject safety
  • History of sensitivity to heparin or heparin-induced thrombocytopenia (if the clinical research unit uses heparin to maintain intravenous cannula patency)
  • A positive pre-study drug/alcohol screen. A minimum list of drugs that will be screened for include amphetamines, barbiturates, cocaine, opiates, cannabinoids and benzodiazepines
  • A positive test for antibody
  • Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period
  • The subject has participated in a clinical trial and has received an product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the study treatment (whichever is longer)
  • Exposure to more than four new chemical entities within 12 months prior to the first dosing day
  • Unwillingness or inability to follow the procedures outlined in the protocol
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
61 participants (actual)

Study arms

  • Experimental
    GSK1278863 (Part A)

    All subjects will receive a single, oral 500 mg dose of GSK1278863 on Day 1 administered as 5 x 100 mg tablets of GSK1278863. Additional doses/cohorts may be added depending upon the emerging safety, tolerability, pharmacokinetic and/or pharmacodynamics findings at the 500 mg dose level in Part A

    Drug: GSK1278863 500 mg

  • Experimental
    GSK1278863 (75 mg/500 mg)/Moxifloxacin 400 mg/Placebo (Part B)

    Subjects will be assigned to one of four treatment sequences (A-1 x Moxifloxacin placebo tablet, 3 x 25 mg tablets of GSK1278863, 2 x GSK1278863 matched placebo; B-1 x Moxifloxacin placebo tablet, 5 x 100 mg tablets of GSK1278863; C-1 x Moxifloxacin placebo tablet, 5 x GSK1278863 matched placebo tablets; D-1 x 400 mg Moxifloxacin tablet, 5 x GSK1278863 matched placebo tablets) (ABDC, BCAD, CDBA, DACB) in accordance with the randomization schedule

    Drug: GSK1278863 75 mg · Drug: GSK1278863 500 mg · Drug: Moxifloxacin 400 mg · Drug: Placebo matching GSK1278863 · Drug: Placebo matching Moxifloxacin

Interventions

  • A round, biconvex, white film coated tablet available in two doses (25 and 100 mg)

  • A round, biconvex, white film coated tablet available in two doses (25 and 100 mg)

  • Oblong, dull red, film-coated, convex tablets with M400 on one side

  • DrugPlacebo matching GSK1278863

    A round, biconvex, white film coated tablet as matching placebo for GSK1278863

  • DrugPlacebo matching Moxifloxacin

    Capsule shaped white film coated tablet as matching placebo for Moxifloxacin

06

What researchers measure

Primary outcomes

  1. Composite of pharmacokinetic (PK) parameters for GSK1278863 and its metabolites for Part A

    Plasma concentrations of GSK1278863 and its metabolites (GSK2391220 \[M2\], GSK2506104 \[M3\], GSK2487818 \[M4\], GSK2506102 \[M5\], GSK2531398 \[M6\], and GSK2531401 \[M13\]) and derived pharmacokinetic parameters including maximum observed concentration (Cmax), Time of occurrence of Cmax (tmax), Area under the concentration-time curve (AUC)

    Time frame: Pre Dose, 0.25hour (h), 0.5h, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 12h, 18h, and 24h post dose in each treatment period

  2. Change from baseline in QT duration corrected for heart rate by Fridericia's formula (QTcF) interval for Part B

    Change from baseline in QTcF interval at each time-point (average of at least three 12-lead Holter ECG replicates per time-point (Pre-dose, Day 1 \[0.25h, 0.5h, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 12h, 18h\] and 24h) for 75 and 500 mg dose of GSK1278863 as compared with time-matched placebo

    Time frame: At each treatment period (there are 4 periods) up to 24 hours

  3. Assessment of 12-lead ECG for Part A

    12-lead ECGs will be obtained at each time-point

    Time frame: Up to Week 3

  4. Assessment of Vital Signs for Part A

    Vital Signs includes. temperature, systolic and diastolic blood pressure (BP) and pulse

    Time frame: Up to Week 3

  5. Number of participants with Adverse Events (AE) for Part A

    An AE is any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product

    Time frame: Up to Week 3

  6. Assessment of Clinical Laboratory Tests for Part A

    Clinical Laboratory Tests includes Hematology, Clinical Chemistry and Urinalysis

    Time frame: Up to Week 3

Secondary outcomes

  1. Change from baseline in QT duration corrected for heart rate by Bazett's formula (QTcB), heart rate (HR), PR, QRS, and QT interval corrected for heart rate (QTci/QTciL interval) for GSK1278863 for Part B

    Change from baseline in QTcB, HR, PR, QRS and QTci/QTciL interval at each time-point (average of at least 3 12-lead Holter ECG replicates per time-point) for 75 mg and 500 mg dose of GSK1278863 as compared with time-matched placebo

    Time frame: Up to Week 9

  2. Change from baseline in QTcB, HR, PR, QRS, and QTci/QTciL interval for moxifloxacin for Part B

    Change from baseline in QTcF, QTcB, and QTci/QTciL interval at each time-point (average of at least 3 12-lead Holter ECG replicates per time-point) for 400 mg dose of moxifloxacin as compared with time-matched placebo

    Time frame: Up to Week 9

  3. Composite of PK parameters for GSK1278863, its metabolites and moxifloxacin for Part B

    Plasma concentrations of GSK1278863, and its metabolites GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), and GSK2531401 (M13), moxifloxacin, and derived pharmacokinetic parameters including Cmax, tmax, AUC

    Time frame: Pre-dose, 0.25h, 0.5h, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 12h, 18h, and 24h in each treatment period of part B

  4. Maximal change from baseline in ECG parameters for Part B

    Maximal change from baseline in ECG parameters for QTcF and QTcB

    Time frame: Up to Week 9

  5. Change from baseline for other ECG parameters for Part B

    Change from baseline at each time-point for other cardiac electrophysiological parameters: QT, QRS, RR, PR and ventricular rate

    Time frame: Up to Week 9

  6. Change in QTc Cmax for Part B

    Evaluate the slope of the relationship and the predicted median (90% confidence interval \[CI\]) value of change in QTc Cmax following therapeutic doses

    Time frame: Up to Week 9

  7. Assessment of Vital Signs for Part B

    Vital Signs includes. temperature, systolic and diastolic blood pressure and pulse

    Time frame: Up to Week 9

  8. Number of participants with Adverse Events in Part B

    An AE is any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product

    Time frame: Up to Week 9

  9. Assessment of Clinical Laboratory Tests for Part B

    Clinical Laboratory Tests includes Hematology, Clinical Chemistry and Urinalysis

    Time frame: Up to Week 9

  10. ECG assessment as a safety measure in Part B

    Triplicate 12-lead ECGs will be obtained at each time-point (Day -1, Pre-dose, Day 1 \[0.25h, 0.5h, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 12h, 18h\], Day 2 \[24h\])during the study using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and QTc intervals

    Time frame: Up to Week 9

07

Study locations

1 site
  • GSK Investigational Site
    Overland Park, Kansas 66211, United States
08

References and documents

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2014 to primary completion in Mar 2015, 3 months.

Of 34 industry-sponsored phase 1 interventional studies under Anemia, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 30. This study's 3 months is below that.

Counting every sponsor, half of 48 studies reached it within 12 months; a quarter within 3 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2014
First posted
Nov 18, 2014
StartActual
Nov 17, 2014
Primary completionActual
Mar 10, 2015
CompletionActual
Mar 10, 2015
Last update
Jul 24, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02293148
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Nov 18, 2014
Start date
Nov 17, 2014
Primary completion
Mar 10, 2015
Completion
Mar 10, 2015
Last update
Jul 24, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GSK1278863

Start the discussion